Luna-Ortiz P, Serrano-Valdés X, Lupi E, Pastelín G

Language: Spanish
References: 81
Page: 92-102
PDF size: 281.34 Kb.

ABSTRACT

Opioid peptides and exogenous opioid are known to exert important cardiovascular effects. Activation of specific receptors result in a potent cardio protective effect to reduce infarct size in experimental animal and to reduce cell death in isolated cardiomiocytes. Nonselective opioid receptors antagonist such as naloxone and a selective delta 1-opioid receptors antagonist, have been shown to inhibit the cardioprotective effect of ischemic preconditioning, a phenomenon in which brief period of ischemia protect the heart against a more prolonged period of ischemia. Selective delta 1 agonist have been shown to exert potent cardioprotective effects in intact animals and cardiac myocytes via activation of G i/o proteins, protein kinase C, and mitochondrial Katp channels. Opioid have been used clinically to manage pain peri-and postoperatively. The demonstration that opioid receptors, most notably delta 1, which not only have analgesic properties, but may now have the potential to protect the myocardium during cardiac surgical interventions, suggests a possible new pharmacological approach for the treatment of patients suffering from acute or chronic myocardial ischemia.

REFERENCES

1. Krumins SA, Faden AL, Feuerstein G. Diprenorphine binding in rat heart. Biochem Biophys Res Commun 1985;127:120-8.

2. Hahnbauer IGD, Kelly GD, Saiani L. Metenkephalin-like peptides of the adrenal medulla. Peptides 1982;3:469-73.

3. Holaday JW. Cardiovascular effects endogenous opiate systems. Annu Rev Pharmacol 1983;23:541-594.

4. Lang RE, Bruckner UB, Kempf B, et al. Opioid peptides and blood pressure regulation. Clin Exp Hypertens 1982;A4:249-69.

5. Bolme P, Fuxe K, Agnati LF, Bradley R, Smythies J. Cardiovascular effects of morphine and opioid peptides following intracisternal administration. Eur J Pharmacol 1978;48:319-24.

6. Lee AYS. Endogenous opioid peptides and cardiac arrhythmias. Int J Cardiol 1990;27:145-51.

7. Lee AYS, Zhan CY, Wong TM. Effects of B-endorphin on the contraction and electrical activity of the isolated perfused rat heart. Int J Pept Prot Res 1984;24:525-8.

8. Lee AYS, Wong TM. Effects of dynorphin 1-13 cardiac rhythm and cyclic adenosine monophosphate levels in the isolated perfused rat heart. Neurosci Lett 1987;80:289-92.

9. Faden AI, Holaday JW. Opiate antagonists: a role in the treatment of hypovolemic shock. Science 1979;205:317-8.

10. Fagbemi O, Lepran I, Parrat JR. Naloxone inhibits early arrhythmias resulting from acute coronary ligation. Br J Pharmacol 1982;76:504-6.

11. Dirksen R. Naloxone in shock. Lancet 1980;20/27:1360-1.

12. Zhan CY, Lee AYS, Wong TM. Naloxone blocks the cardiac effects of myocardial ischemia and reperfusion in the isolated rat heart. Clin Exp Pharmacol Physiol 1985;52:373-78.

13. Huang XD, Lee AYS, Wong TM. Naloxone inhibits arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized dogs. Br J Pharmacol 1988;87:475.

14. Hug J, Gross GJ, Nagase H, Lian BT. Protection of cardiac myocytes via delta 1 opioid receptors, protein kinase C, and mitochondrial K atp channels. Am J Physiol Heart Circ Physiol 2001;280:H377-H39.

15. Liang BT, Gross GJ. Direct preconditioning of cardiac myocytes via opioid receptors and Katp channels. Circ Res 1999;84:1396-99.

16. Sigg DC, Coles JA Jr, Oeltgen PR, Iaizzo PA. Role of delta receptor agonist on infarct size reduction in swine. Am J Physiol Heart Circ Physiol 2002;282:H1953-H1957.

17. Wu S, Li HY, Wong TM. Cardioprotection of preconditioning by metabolic inhibition in the rat ventricular myocyte. Involvement of kappa-opioid receptor. Cir Res 1999;84:1388-1392.

18. Coles JA Jr, Sigg DC, Iaizzo PA. The role of kappa-opioid receptor activation in pharmacological preconditioning of swine. Am J Physiol Heart Circ Physiol. (in press).

19. Wang GY, Wu, S, Pei JM, et al. Kappa but not delta-opioid receptors mediate effects of ischemic preconditioning on both infarct and arrhythmia in rats . Am J Physiol Heart Circ Physyol 2001;280:H384-H386.

20. Bell SP, Sack MN, Patel A, et al. Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J Am Coll Cardiol 2000;36:2296-2298.

21. Kato R, Foex P. Myocardial protection by anesthetic agents against ischemia-reperfusion injury: an update for anesthesiologist. Can J Anaesth 2002;49:777-782.

22. Benson CJ, Eckert SP, Mc Cleskey EW. Acid–evoked current in cardiac sensory neurons: a possible mediator of myocardial ischemic sensation. Circ Res 1999;84:921-928.

23. Villemagne PSR, Dannals RF, Ravert HT, Frost J. PET imaging of human cardiac opioid receptors. Eur J Nucl Med 2002;29:1385-1388.

24. Barron BA. Opioid peptides and the heart. Cardiovasc Res 1999;43:13-16.

25. Fryer RM, Hsu AK, Nagase H, Gross GJ. Opioid–induced cardioprotection against myocardial infarction and arrythmias. J Pharmacol Exp Ther 2000;294:451-457.

26. Robbins GR, Wynands JE, Whalley DG, et al. Pharmacokinetics of alfentanyl and clinical responses during cardiac surgery. Can J Anesth 1990;37:52-57.

27. Hug CC Jr, Hall RI, Angert KC, et al. Alfentanyl plasma concentration vs effect relationships in cardiac surgical patients. Br J Anesth 1988;61:435-440.

28. Feldman PD, Parveen N, Sezen S. Cardiovascular effects of leu-enkephalin in the nucleus tractus solitarious of the rat. Brain Res 1996;709:331-333.

29. Thompson IR, Putnins CL, Friesen RM. Hyperdynamic cardiovascular responses to anesthetic induction with high–dose fentanyl. Anesth Analg 1986;65:91-95.

30. Zhang CC, Su JY, Calkins D. Effects of alfentanyl on isolated cardiac tissues of the rabbit. Anesth Analg 1990;71268-274.

31. Nakae Y, Fujita S, Namiki A. Morphine enhances myofilament calcium sensitivity in intact guinea pig beating hearts. Anesth Analg 2001;92:602-608.

32. Mathews HM, Furness G, Carson IW, et al. Comparison of sufentanyl –oxygen and fentanyl –oxygen anesthesia for coronary artery bypass grafting. Br J Anesth 1988;60:530-535.

33. Zaug M, Lucchinetti E, Spahn DR, et al. Differential effects of anesthetics on mitochondrial Katp channel activity and cardiomyocite protection. Anesthesiology 2002;97:15-23.

34. Duman A, Saide Sahin A, Esra Atalik K, et al. The in vitro effects of remifentanyl and fentanyl on isolated human right atria. J Cardiothorac Vasc Anesth 2003;17:465-469.

35. Ogletree ML, Sprung J, Moravec CS. Effects of remifentanyl on the contractility of failing human heart muscle. J Cardiothorac vasc anesth 2005;19:763-767.

36. Lakata EG, Guanieri T. Spontaneous myocardial calcium oscillation: Are they linked to ventricular fibrillation? J Cardiovasc Electrophysiol 1993;4:473-489.

37. Hussain M, Orchard CH. Sarcoplasmic reticulum calcium content, L-type calcium current and the calcium transient in rat myocites during adrenergic stimulation. J Physiol 1997;505:385-402.

38. Yu XC, Li HY, Wang HX, Wong TM. U50, 488H inhibits effects of norepinephrine in rat cardiomyocytes. J Mol Cell Cardiol 1998;30;405-413.

39. Yu XC, Wang HX, Pei JM, Wong TM. Anti-arrhythmic effect of Kappa opioid receptor stimulation in the perfused rat heart: involvement of cAMP dependent pathway. J Mol Cell Cardiol 1999;31:1809-1809.

40. Pepe S, Xiao R, Hohl C, Altschuld R, Lakata E. Cross talk between opioid peptide and adrenergic receptor signaling in isolated rat heart. Circulation 1997;95:2122-2129.

41. Podzuweit T, Els D, NcArthy J. Cyclic AMP mediated arrhythmias induced in the ischemic pig heart. Basic Res Cardiol 1981;76:443-448.

42. Wu J, Chen T, Lee A. Opioids in myocardial ischemia. Eur Heart J 1993;14:1273-1277.

43. Schultz J, Hsu A, Nagase H, Gross G. TAN 67, a delta 1 opioid receptor agonist, reduces infarct size via activation of G i/o proteins and Katp channels. Am J Physiol 1998;274:H909-H914.

44. Wilde A. Katp channel opening and arrhythmogenesis. J cadiovasc Pharmacol 1994;24:S35-S40.

45. Lishmanov Y, Maslov L, Ugdyzhekova D. Participation of central and peripheral opioid receptors in arrhyhmogenesis. Clin Exp Pharmacol Physiol 1999;26:716-723.

46. Fryer RM, Hsu AK, Nagase H, Gross GJ. Opioid – induced cardioprotection against myocardial infarction and arrhythmias: Mitochondrial versus sarcolemmal ATP sensitive potassium channels. J Pharmacol Exp Therap 2000;294:451-45.

47. Schultz J, Rose E, Yao Z, Gross G. Evidence for involvement of opioid receptors in ischemic preconditioning in rat heart. Am J Physiol 1995;268:H2157-H2161.

48. Schultz J, Hsu A, Gross G. Ischemic preconditioning in the intact rat heart is mediated by delta 1 but not mu or kappa opioid receptors. Circulation 1998;97:1282-1289.

49. Miki T, Cohen M, Downey J. Opioid receptor contributes to ischemic preconditioning through protein kinase C activation in rabbits. Mol Cell Biochem 1998;186:3-12.

50. Mayfield KP, DAlecy LG. Role of endogenous opioid peptides in the acute adaptation to hypoxia. Brain Res 1992;582:226-231.

51. Mayfield KP. DAlecy LG. Delta 1 opioid agonist acutely increases hypoxic tolerance. J Pharmacol Exp Ther 1994;268:683-688.

52. Chien S, Oeltgen PR, Diana JR, Salley RK, Su TP. Extension of tissue survival time in multiorgan block preparation with a delta opioid DADLE. J Thorac Cardiovasc Surg 1994;107:964-967.

53. Takasaki Y, Wolff RA, Chien GL, Van Winkle DM. Met 5-enkephalin protects isolated adult rabbit cardiomyocytes via delta opioid receptors. Am J Physiol 1999;277:H2442-H2450.

54. Benedict PE, Benedict MB, Su TP, Bolling SF. Opiate drugs and delta receptor-mediated myocardial protection. Circulation 1999;100:357-360.

55. Kato R, Ross S, Foex P. Fentanyl protect the heart against ischaemic injury via opioid receptors. Br J Anesth 2000;84:204-214.

56. Kato R, Foex P. Fentanyl reduces infarction but not stunning via delta-opioid receptors and protein kinase C in rats. Br J Anesth 2000;84:608-614.

57. Schwartz CF, Georges AJ, Gallager MA, et al. Delta opioid receptors and low temperature myocardial protection. Ann Thorac Surg 1999;68:2089-2092.

58. Zhan ZY, Lee AYS, Wong TM. Naloxone blocks the cardiac effects of myocardial ischemia and reperfusion in the rat isolated heart. Clin Exp Pharmacol Physiol 985;12:373-378.

59. Liang C, Imai N, Stone CK, Woolf PD. The role of endogenous opioids in congestive heart failure. Circulation 1987;75:443-451.

60. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-36.

61. Tomai F, Crea F, Chiariello L, Gioffe PA. Ischemic preconditioning in humans. Models, mediators, and clinical relevance. Circulation 1999;100:559-563.

62. Rubino A, Yellon DM. Ischemic preconditioning of the vasculature: an overlooked phenomenon for protecting the heart? Trends Pharmacol Sci 2000;21:225-230.

63. Okubo S, Xi L, Bernardo NL, Yoshida K. Myocardial preconditioning: basic concepts and potential mechanism. Mol Cell Biochem 1999;196:3-12.

64. Liang BT, Gross GJ. Direct preconditioning of cardiac myocytes via opioid receptors and Katp channels. Cir Res 1999;84:1396-1400.

65. Bell SP, Sack MN, Patel A, Opie LH. Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J Am Col Cardiol 2000;36:2296-2302.

66. Schultz JEJ, Gross GJ. Opioid and cardioprotection. Pharmacol Ther 2001;89:123-137.

67. Zamir N, Shuber E. Altered pain perception in hypertensive human. Brain Res 1980;201:471-474.

68. Feuerstein G, Siren AL. The opioid peptides: a role in hypertension. Hypertension 1987;9:561-565.

69. Diamond GA, Forrester JS, de Luz PL, et al. Post extrasystolic potentiation of ischemic myocardium by atrial stimulation. Am Heart J 1978;95:204-9.

70. Rahintoola S. The Hibernating myocardium. Am Heart J 1989;117:211-221.

71. Oeltgen PR, Welborn JR, Nuchols PA, Spurrier WA, Bruce DS. Opioid and hibernation. Life Sci 1987;41:2115-2120.

72. Oeltgen PR, Nilekani SP, Nuchols PA, Spurrier WA. Further studies on opioids and hibernation. Life Sci 1988;43:1565-1574.

73. Oeltgen PR, Horton ND, Bolling SF, Su TP. Extended lung preservation with the use of hibernation trigger factors. Ann Thorac Surg 1966;61:1488-1493.

74. Bolling SF, Su TP, Childs KF, Ning XH, Horton N, Kilgore K, Oeltgen PR. The use of hibernation induction triggers for cardiac transplant preservation. Transplantation 1997;63:326-329.

75. Bolling SF, Tramontini NL, Kilgore KS, Su TP, Oeltgen PR, Harlow HH. Use of “natural” hibernation induction triggers for myocardial protection. Ann Thorac Surg 1997;64:623-627.

76. Dawe AR, Spurrier WA. Hibernation induced in ground squirrels by blood transfusion. Science, 1969;163:298-299.

77. Oeltgen PR, Spurrier WA. Survical in the cold. In: Mussachia SJ, Jansky L, eds. Hibernation and Other Adaptation. New York: Elsevier North Holland; 1981:139-157.

78. Su TP, Oeltgen PR, Nuchols PA, Nilekani SP, Spurrier WA. Delta opioid receptor ligand selectively induced hibernation in summer active ground squirrels. Fed Proc 1988;2:1074-1076.

79. Dawe AR, Spurrier Wa, Armour JA. Summer hibernation induced by a cryogenically preserved blood “trigger”. Science 1970;168:497-498.

80. Bolling SF, Oeltgen PR, Horton ND, Kilgore K, Su TP. The use of hibernation induction for cardiac transplant preservation. Transplantation. 1997;63:326-329.

81. Binder W, Machelska H, Mousa S, Schmitt T, et al. Analgesic and antiinflammatory effects of two novel kappa- opioid peptides. Anesthesiology 2001;94:1034-1044.